US Pharmas Display Defensive Mettle But Headwinds Mount
Executive Summary
US big pharma manufacturers generally delivered sales and earnings growth in the second quarter and reaffirmed guidance despite currency headwinds; US drug pricing legislation could present a tipping pressure point.
You may also be interested in...
Medicare Price ‘Negotiation’ Process Gets Broad Brush Treatment In New Law
With enactment of the drug pricing reform provisions in the Inflation Reduction Act, stakeholders now turn their attention to the implementing regulations that will be developed by the Centers for Medicare and Medicaid Services.
As Lilly’s Realized Sales Prices Drop, Ricks Reiterates Criticism Of US Drug Price Plan
With Lilly’s sales narrative hampered by global price pressures, Lilly CEO David Ricks again criticized drug price negotiation proposals before Congress. Mounjaro launch offers a bright spot, exceeding projections.
Pharma Braces For Potential Landmark Moment For US Drug Price Controls
US drug pricing legislation that has picked up momentum could stymie R&D investment and curb the revenue tail for some big drugs, industry says, but CEOs also expect they can navigate the challenge.